How to Get Rezdiffra (Resmetirom) in Oregon

What Is Rezdiffra and Why Does It Matter for Oregon Patients?

Rezdiffra (resmetirom) is the first FDA-approved oral medication specifically targeting MASH with liver fibrosis. The FDA granted accelerated approval in March 2024 based on the MAESTRO-NASH trial, which enrolled 966 patients with biopsy-confirmed MASH and fibrosis stages F1b through F3. At 52 weeks, 26% of patients on the 80 mg dose and 30% on the 100 mg dose achieved MASH resolution without worsening fibrosis, compared to 10% on placebo [1].

Why Oregon Residents Need a Clear Access Path

Before resmetirom, no approved pharmacotherapy existed for MASH. Oregon has an estimated 300,000+ adults with non-alcoholic fatty liver disease (NAFLD/MASLD), and roughly 20% of those may have progressed to MASH according to CDC prevalence data. Many Oregon patients, particularly those in rural counties east of the Cascades, face limited specialist access. Telehealth and 503A pharmacy shipping solve geographic barriers that would otherwise delay treatment.

Mechanism of Action

Resmetirom is a thyroid hormone receptor-beta (THR-beta) selective agonist. It reduces hepatic fat by activating lipid metabolism pathways in the liver without systemic thyroid effects on the heart, bone, or muscle. This selectivity distinguishes it from older thyroid hormone analogs that caused off-target toxicity [2].

Step-by-Step: Getting a Rezdiffra Prescription in Oregon

The process from first consultation to filled prescription typically takes one to four weeks. Here is the sequence most Oregon patients follow.

Step 1: Confirm Your Diagnosis

Rezdiffra carries an FDA-indicated use for MASH with fibrosis stage F2 or F3, confirmed by liver biopsy or an FDA-recognized non-invasive diagnostic method. Accepted alternatives to biopsy include FibroScan (vibration-controlled transient elastography), the Enhanced Liver Fibrosis (ELF) test, and the FIB-4 index used in conjunction with imaging. Your prescriber will need documentation of fibrosis staging before writing the prescription.

Step 2: Choose Your Provider Type

Oregon law permits MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) with independent or collaborative prescriptive authority to prescribe Rezdiffra. Gastroenterologists and hepatologists are the most common prescribers, but primary care providers comfortable with MASH management can prescribe if fibrosis staging documentation is available.

Step 3: Complete Baseline Labs

Standard pre-prescribing labs include:

• Comprehensive metabolic panel (CMP) with ALT, AST, and bilirubin
• Thyroid function panel (TSH, free T4) to rule out uncontrolled thyroid disease
• Lipid panel (resmetirom lowers LDL-C; baseline measurement informs monitoring)
• FIB-4 score calculation or FibroScan result
• Pregnancy test for women of childbearing potential

Step 4: Submit Prior Authorization (If Applicable)

Oregon Medicaid (Oregon Health Plan) covers Rezdiffra with prior authorization. Commercial plans vary. The prior authorization packet typically requires fibrosis staging documentation, a diagnosis code for MASH (K75.81), baseline liver function labs, and confirmation that the patient does not have decompensated cirrhosis (Child-Pugh B or C).

Step 5: Fill the Prescription

Once approved, the prescription routes to a specialty pharmacy or a 503A compounding pharmacy licensed in Oregon. Most patients receive their medication within 3-7 business days after PA approval.

Telehealth Access to Rezdiffra in Oregon

Oregon's telehealth framework permits prescribing of non-controlled substances after a synchronous audio-video visit. Rezdiffra is not a controlled substance, so it qualifies for telehealth prescribing without an in-person requirement.

How Telehealth Visits Work

A telehealth hepatology or GI consultation follows the same clinical workflow as an in-person visit. The provider reviews your imaging, lab results, and medical history during the video appointment. If fibrosis staging has already been completed at a local lab or imaging center, no additional in-person visit is needed before prescribing.

Choosing a Telehealth Provider

Look for providers who meet these criteria: board certification in gastroenterology, hepatology, or endocrinology; Oregon medical license; experience prescribing Rezdiffra specifically; and willingness to coordinate with your local PCP for ongoing monitoring. HealthRX connects Oregon patients with licensed prescribers who specialize in MASH pharmacotherapy via telehealth.

Oregon Medical Board Telehealth Rules

The Oregon Medical Board (OMB) requires that a provider-patient relationship be established before prescribing. A synchronous video visit satisfies this requirement per ORS 677.135. No separate in-person visit is mandated for new patients receiving non-controlled prescriptions.

Oregon Medicaid (Oregon Health Plan) Coverage

Oregon Medicaid covers Rezdiffra with prior authorization under the Oregon Health Plan's prioritized list. MASH with moderate-to-advanced fibrosis appears on the funded condition list, making coverage accessible to OHP members who meet clinical criteria.

Prior Authorization Requirements

Oregon Medicaid PA submissions require:

1. Documented MASH diagnosis (ICD-10: K75.81)
2. Fibrosis staging of F2 or F3 by biopsy, FibroScan (LSM ≥ 8.0 kPa), or validated serum biomarker
3. Prescriber attestation that the patient does not have decompensated cirrhosis
4. Baseline ALT/AST values
5. Documentation that lifestyle modifications (diet, exercise) have been attempted

Timeline for PA Decisions

Oregon Health Plan coordinated care organizations (CCOs) must respond to standard PA requests within 14 calendar days. Urgent requests receive a 72-hour turnaround. Most Rezdiffra PAs are processed within 5-7 business days in practice.

Commercial Insurance in Oregon

Major commercial carriers operating in Oregon (Providence Health Plan, Regence BlueCross BlueShield, Moda Health, PacificSource) have begun adding Rezdiffra to specialty tiers. Coverage criteria mirror the FDA label: confirmed MASH with F2-F3 fibrosis, no decompensated cirrhosis. Expect a specialty tier copay ranging from $50-$150/month with manufacturer copay assistance potentially reducing out-of-pocket costs further.

Pharmacy Options in Oregon

Oregon patients have two primary pharmacy pathways for obtaining Rezdiffra: specialty retail pharmacies and 503A compounding pharmacies.

Specialty Pharmacies

Most large pharmacy benefit managers (PBMs) route Rezdiffra through their specialty pharmacy networks. In Oregon, specialty pharmacy locations operated by Optum Specialty, CVS Specialty, and Accredo can fill and ship Rezdiffra prescriptions. These pharmacies handle the PA process on behalf of the prescriber in many cases.

503A Compounding Pharmacies

Oregon-licensed 503A compounding pharmacies may compound resmetirom pursuant to a valid patient-specific prescription. The Oregon Board of Pharmacy permits 503A pharmacies to ship compounded medications to patients within the state. This pathway may offer cost advantages for patients without insurance coverage, though compounded versions are not AB-rated equivalents of the branded product.

Shipping and Delivery

Both specialty and compounding pharmacies in Oregon ship statewide, including to rural areas. Resmetirom is an oral tablet stored at room temperature, so no cold-chain shipping is required. Standard ground delivery is sufficient.

Required Labs and Monitoring in Oregon

Ongoing monitoring while taking Rezdiffra follows the FDA prescribing information and hepatology society guidelines.

Baseline Testing

Before starting Rezdiffra, your provider will order a comprehensive metabolic panel, thyroid function tests, lipid panel, and fibrosis assessment. These establish reference values for tracking treatment response.

Ongoing Monitoring Schedule

The recommended monitoring schedule includes:

• Liver function tests (ALT, AST, bilirubin) at weeks 4, 8, and 12, then every 3 months
• Lipid panel at 12 weeks (resmetirom typically lowers LDL-C by 13-16%)
• Thyroid function at 12 weeks if baseline TSH was borderline
• FibroScan or non-invasive fibrosis assessment at 12 months to evaluate treatment response

Where to Get Labs in Oregon

Quest Diagnostics and LabCorp both operate draw sites throughout Oregon. FibroScan is available at most gastroenterology practices in Portland, Salem, Eugene, Bend, and Medford. For patients in rural areas, mobile FibroScan services and telehealth follow-up provide a practical workaround.

Clinical Evidence Supporting Rezdiffra

The evidence base for resmetirom centers on the MAESTRO-NASH phase 3 trial and supporting data from the MAESTRO-NAFLD-1 safety study.

MAESTRO-NASH Results

The MAESTRO-NASH trial randomized 966 adults with biopsy-confirmed MASH (fibrosis stages F1b-F3) to resmetirom 80 mg, 100 mg, or placebo [1]. At 52 weeks:

• MASH resolution without fibrosis worsening: 26% (80 mg) and 30% (100 mg) vs. 10% (placebo)
• Fibrosis improvement by ≥1 stage without NASH worsening: 24% (80 mg) and 26% (100 mg) vs. 14% (placebo)
• LDL-C reduction: approximately 13-16% from baseline

The 100 mg dose is indicated for patients weighing ≥100 kg; the 80 mg dose for those weighing <100 kg [2].

Safety Profile

In MAESTRO-NASH, the most common adverse events were diarrhea (27% vs. 18% placebo) and nausea (22% vs. 13% placebo), typically mild and self-limiting within the first 4 weeks. Serious hepatic events were rare and similar between groups. No clinically significant thyroid-related adverse events occurred, supporting the THR-beta selectivity of the drug [1].

Long-Term Data

The ongoing MAESTRO-NASH 72-week and open-label extension data will inform the confirmatory endpoint (clinical outcomes including progression to cirrhosis). The FDA's accelerated approval pathway requires Madrigal to complete these confirmatory studies by 2028 [3].

Who Should Not Take Rezdiffra

Rezdiffra is contraindicated in patients with decompensated cirrhosis (Child-Pugh class B or C). The FDA label also advises caution in patients with active thyroid disease or those taking thyroid hormone replacement, though mild hypothyroidism on stable levothyroxine is not an absolute contraindication. Pregnant patients should not take resmetirom based on animal reproductive toxicity data [2].

Cost and Financial Assistance in Oregon

The wholesale acquisition cost (WAC) of Rezdiffra is approximately $47,400 per year. Out-of-pocket costs vary significantly based on insurance type.

Reducing Out-of-Pocket Costs

Madrigal Pharmaceuticals offers a copay assistance program for commercially insured patients, potentially reducing monthly copays to $0-$10. For uninsured patients, a patient assistance program (PAP) provides Rezdiffra at no cost for those meeting income eligibility criteria (typically <400% federal poverty level). Oregon Health Plan members have no copay for approved prescriptions under most CCO benefit designs.

503A Compounding Price Comparison

Compounded resmetirom through a 503A pharmacy may cost $200-$600 per month without insurance, depending on the pharmacy and dose. This represents a significant savings over the branded WAC for cash-pay patients, though patients should confirm bioequivalence discussions with their prescriber.

Timeline: From Consultation to First Dose

The typical Oregon patient timeline:

• Day 1-3: Telehealth or in-person consultation, lab orders placed
• Day 3-7: Labs drawn, FibroScan completed (if not already done)
• Day 7-10: Results reviewed, prescription written, PA submitted
• Day 10-21: PA approved (5-14 days depending on urgency designation)
• Day 21-28: Medication shipped and received

Patients with existing fibrosis documentation and recent labs can compress this timeline to under two weeks.